#ORPH. Cathal Friel, Open Orphan CEO explains how he plans to buy and build a pharma services company. He believes the pharma rare orphan asset space is the hot spot at the moment, and providing services to those pharmas hoping to commercialise drugs is the strategy.
Open Orphan have been building a pharma contacts platform for a couple of years and recently reversed Open Orphan into a business called Venn Life Sciences, giving them an AIM listing and pre-exisisting revenues of £14M.
#ORPH have just raised £4.5M from institutions and have been looking at acquisitions. The services sector is very fragmented and Orphan see a consolidation opportunity.